文献速递心境障碍

双相障碍抗癫痫类心境稳定剂治疗反应的药物基因组学研究:MoStGen联盟研究

Pharmacogenomics of antiepileptic drug mood stabilizer treatment response in bipolar disorder: A MoStGen Consortium study.
PubMed 文献 · Mol Psychiatry · 2026-02-19

MoStGen联盟基于917名双相障碍个体,用Alda量表定量评估抗癫痫类心境稳定剂(AMS)治疗反应,开展全基因组关联分析与多基因评分分析。发现拉莫三嗪(LTG)治疗反应与ROBO2基因(rs985123,p=1.9E-10)及POLR1E基因水平(p=2.53E-06)显著关联,总体AMS与丙戊酸(VPA)反应未见显著关联;癫痫多基因评分与AMS反应名义显著相关(p=0.024)。

要点

  • LTG治疗反应与ROBO2基因rs985123全基因组显著关联(p=1.9E-10)。
  • POLR1E基因水平与LTG反应显著关联(p=2.53E-06)。
  • 癫痫多基因评分与AMS反应名义显著相关(p=0.024)。

核心结论

  • AMS治疗反应存在多基因信号,LTG反应与ROBO2及POLR1E基因相关。
  • 总体AMS与VPA治疗反应未检出全基因组显著关联。
  • 癫痫遗传易感性较高者可能对AMS治疗反应更好。

研究设计与样本

  • MoStGen联盟多中心数据,纳入917名双相障碍个体。
  • 采用Alda量表定量评估AMS治疗反应。
  • 分亚队列行全基因组关联分析后行荟萃分析,并按VPA与LTG分层分析。
  • 采用多基因评分分析评估遗传贡献及神经精神疾病遗传易感性对AMS反应的影响。

主要发现

  • LTG治疗反应与ROBO2基因SNP rs985123全基因组显著关联(p=1.9E-10)。
  • LTG治疗反应与POLR1E基因水平显著关联(p=2.53E-06)。
  • 总体AMS与VPA治疗反应未见显著关联。
  • 留一法多基因评分分析为AMS治疗反应提供显著多基因信号证据。
  • 癫痫多基因评分与AMS反应名义显著相关(p=0.024),提示癫痫遗传易感性越高AMS反应越好。

关键数值与推荐

  • 全基因组显著阈值按常规GWAS标准,LTG反应ROBO2 top SNP rs985123 p=1.9E-10。
  • POLR1E基因水平p=2.53E-06。
  • 癫痫多基因评分与AMS反应关联p=0.024(名义显著)。

临床怎么用

  • ROBO2与POLR1E相关信号有望辅助预测双相障碍患者对LTG的治疗反应。
  • 癫痫多基因评分可能提示AMS治疗反应更佳,但仅为名义显著,暂不宜单独用于临床决策。
  • 总体AMS与VPA反应暂无可用遗传预测指标,仍需结合临床因素评估。

局限性

  • 总体AMS与VPA治疗反应未检出显著关联,相关遗传预测证据有限。
  • 癫痫多基因评分与AMS反应的关联仅为名义显著(p=0.024),需进一步验证。
  • 原文未报告样本的详细人口学与临床特征及随访时长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Identifying biological and clinical factors associated with response to mood-stabilizing medications is critical for improving bipolar disorder (BD) treatment. The Mood Stabilizer Genomics (MoStGen) Consortium was established to investigate pharmacogenomic and clinical predictors of response to treatment of BD with antiepileptic drug mood stabilizers (AMS). Here we present the first pharmacogenomic analyses of AMS treatment outcomes based on MoStGen Consortium data, including 917 individuals across contributing sites. We performed genome-wide association analyses in subcohorts followed by meta-analyses, with AMS treatment response measured quantitatively using the Alda scale. Medication-stratified analyses were performed for valproic acid (VPA) and lamotrigine (LTG) treatment response. Additionally, polygenic score (PGS) analyses were used to evaluate the overall genetic contribution to AMS response across cohorts and to test whether genetic liability for various neuropsychiatric illnesses impacts AMS response. We detected genome-wide significant associations with LTG treatment response for SNPs in the gene ROBO2 (top SNP: rs985123, p = 1.9E-10) and for POLR1E at the gene-level (p = 2.53E-06). No significant associations were found for overall AMS or VPA treatment response. Leave-one-out PGS analyses provided significant evidence for a polygenic signal for AMS treatment response. Furthermore, the epilepsy PGS was nominally significantly associated with AMS response (p = 0.024), suggesting higher genetic liability to epilepsy predicts a better response to treatment with AMS. These findings provide insights into the genetic contribution to AMS treatment outcomes, and in particular LTG response, and may contribute to the development of more precise treatments for BD.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Ho AM, Coombes BJ, Batzler A, et al. Pharmacogenomics of antiepileptic drug mood stabilizer treatment response in bipolar disorder: A MoStGen Consortium study. Mol Psychiatry. 2026. PMID: 41714438. doi:10.1038/s41380-026-03478-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。